In April 2018, Digital Diagnostics (formerly known as IDx) became the first company to ever receive FDA clearance for an AI diagnostic platform that makes a diagnosis without physician input. This achievement did not happen overnight – it was the culmination of decades of research by founder Dr. Michael Abramoff on automated image analysis, combined with decades of research on how clinicians diagnose disease. Digital Diagnostics’s first FDA-cleared product is the AI diagnostic platform Dr. Abramoff had envisioned years earlier. The platform, called IDx-DR, detects diabetic retinopathy and macular edema in primary care. After completing a rigorous prospective, a pre-registered clinical trial at primary care sites across the country, IDx-DR became the first FDA-cleared AI diagnostic system to make a diagnosis without physician input.
In Spring 2020, Digital Diagnostics approached Frey with a rebranding and website design project to align with their growth. After a complete brand discovery process, Frey created a new brand and materials that aligned with their forward-thinking and innovative mission. Since the launch of the rebrand, Digital Diagnostics has come back to Frey for additional website enhancements and marketing support.
